Hunterase

Taeyoon Kim

CONTENTS

1	Prot	ein parameters analysis
	1.1	Amino acid composition
	1.2	Potential sites of chemical modification
	1.3	Secondary structure fraction
	1.4	Secondary structure prediction
	1.6	Protein Scales
2	Imm	nunogenicity analysis
	2.1	MHC class 1
	2.2	MHC class 2
	2.3	Appendix

The data in the report is intended to be a resource to guide the development and lead-optimization of a clinical antibody. These data can be used in a preemptive fashion - for example, in the decision to substitute an exposed residue on the antibody surface that may be prone to the kind of chemical modification that might affect the stability of the antibody. They can also be used to assist the troubleshooting of problems that can arise in the course of an antibody's clinical development - for example if an antibody displays stability issues in storage, or unacceptably high levels of immunogenicity in early clinical trials. There is always a great deal of risk involved in the development of any therapeutic molecule but experience has shown that the kind of data presented in this report is an invaluable tool for mitigating that risk - either by helping to identify potential problems before they occur, or by guiding the troubleshooting of problems that can occur during the antibody's development and lead-optimization.

Introduction

This report contains a structure and sequence-based analysis of HUNTERASE. Hunterase® is an enzyme replacement therapy for the treatment of Hunter syndrome (mucopolysaccharidosis type II, MPS II). Since 2012, Hunterase® has been made available in more than ten countries worldwide. The established efficacy and safety of Hunterase® provide a unique treatment option to patients with MPS II.

Mucopolysaccharidosis type II (MPS II, Hunter syndrome)

Mucopolysaccharidosis type II (MPS II) or Hunter syndrome, is a rare, disabling, and often fatal genetic disease, which has been listed on the First National List of Rare Diseases (CRDL) published by the Chinese government1.

The syndrome is caused by the absence or deficiency of a lysosomal enzyme, iduronate-2-sulfatase (IDS), which is required for the degradation of two glycosaminoglycans (GAGs), heparan sulfate and dermatan sulfate. In MPS II, GAGs progressively accumulate throughout the body, causing a variety of disease manifestations and leading to tissue dysfunction, organ failure, and reduced life expectancy. The clinical spectrum of MPS II ranges from a severe form with onset in late infancy to early childhood, manifesting severe somatic disease and central nervous system degeneration, to an attenuated form with onset in mid to late childhood, manifesting less severe somatic disease with mild or no central nervous system involvement.

The main clinical manifestations of MPS II are developmental delay, short stature, coarse facies, multiple skeletal deformities (osteogenesis multiplex), joint contractures, hernias, hepatosplenomegaly, hearing loss, valvular heart disease, hypertrophic cardiomyopathy, obstructive sleep apnea, restrictive lung disease, and frequent respiratory infections. Patients with the severe form may live for up to 10 years to 20 years2, whereas those with the attenuated form often live into mid-adulthood. Enzyme replacement therapy is the standard treatment of MPS II and treatment of symptoms is also required.

MPS II is an X-linked disorder that affects males almost exclusively. The incidence of MPS II is estimated to be higher in East Asian countries (1/51,000-1/93,000 live births in Taiwan3,4) than in predominantly Caucasian countries (1/149,000-1/162,000 live births5,6).

Input sequence

SETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDF NSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCP VDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYN PWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEW AKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVP SFHVELCREGKNLLKHFRFRDLEEDPYLPGNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGF NPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP

CONTENTS 1

Table of contents

- Protein parameters analysis
- Immunogenicity analysis

2 CONTENTS


PROTEIN PARAMETERS ANALYSIS

The program performs most of the same functions as the Expasy ProtParam tool.

- · Molecular weight
 - Amino acids are the building blocks that form polypeptides and ultimately proteins. Calculates the molecular weight of a protein.
- Chemical composition
 - A chemical formula is a way of presenting information about the chemical proportions of atoms that constitute a particular chemical compound or molecule, using chemical element symbols, numbers.
- · Extinction coefficient
 - Extinction (or extinction coefficient) is defined as the ratio of maximum to minimum transmission of a beam
 of light that passes through a polarization optical train. extinction coefficient in units of M-1 cm-1, at 280 nm
 measured in water.
- · Theoretical pI
 - The isoelectric point (pI, pH(I), IEP), is the pH at which a molecule carries no net electrical charge or is electrically neutral in the statistical mean. The pI value can affect the solubility of a molecule at a given pH. Such molecules have minimum solubility in water or salt solutions at the pH that corresponds to their pI and often precipitate out of solution. Biological amphoteric molecules such as proteins contain both acidic and basic functional groups.
- · Aromaticity
 - Calculate the aromaticity according to Lobry, 1994. Calculates the aromaticity value of a protein according to Lobry, 1994. It is simply the relative frequency of Phe+Trp+Tyr.
- GRAVY
 - The GRAVY value is calculated by adding the hydropathy value for each residue and dividing by the length
 of the sequence (Kyte and Doolittle; 1982). A higher value is more hydrophobic. A lower value is more
 hydrophilic.
- Instability_index
 - Implementation of the method of Guruprasad et al. (1990, Protein Engineering, 4, 155-161). This method tests a protein for stability. Any value above 40 means the protein is unstable (=has a short half life).

(continues on next page)

(continued from previous page)




1.1 Amino acid composition

We can easily count the number of each type of amino acid.


- · Number of each amino acids
 - Simply counts the number times an amino acid is repeated in the protein sequence.

```
Total number of positively charged residues(Arg + Lys):-----43

Total number of negatively charged residues(Asp + Glu):-----64
```



· Percent of amino acid contents



1.2 Potential sites of chemical modification

An initial scan of the protein sequences is presented based purely upon sequence. If a structural analysis was also requested, this section should be used in conjunction with the molecular surface analysis described in a subsequent section. Any of the sites listed below could be candidates for further consideration if the molecular surface analysis shows that they are significantly exposed on the surface of the protein, increasing their propensity for chemical modification. The canonical sequence analysis is also helpful here, since each of these sites can also be considered in the context of their frequency of occurrence within the canonical library of homologous sequences.

1.2.1 Potential deamidation positions

Asparagine (N) and glutamine (Q) residues are particularly prone to deamidation when they are followed in the sequence by amino acids with smaller side chains, that leave the intervening peptide group more exposed. Deamidation proceeds much more quickly if the susceptible amino acid is followed by a small, flexible residue such as glycine whose low steric hindrance leaves the peptide group open for attack.

• Search patterns: ASN/GLN-ALA/GLY/SER/THR

```
4-QA-5
6-NS-7
51-NA-52
56-QA-57
81-NS-82
101-NG-102
142-NT-143
175-QS-176
179-QA-180
252-QA-253
273-QS-274
300-NS-301
371-QS-372
451-NS-452
515-QG-516
```

1.2.2 Potential o-linked glycosylation sites

The O-linked glycosylation of serine and threonine residues seems to be particularly sensitive to the presence of one or more proline residues in their vicinity in the sequence, particularly in the 2-1 and +3 positions.

• Search patterns: PRO-SER/THR

```
24-PS-25
61-PS-62
135-PS-136
383-PT-384
400-PS-401
444-PS-445
455-PS-456
```

• Search patterns: SER/THR-X-X-PRO

```
92-STIP-95

129-SFPP-132

190-SASP-193

223-TLAP-226

330-THVP-333

380-SLFP-383

439-SQYP-442

445-SDIP-448

452-SDKP-455
```

1.2.3 Potential n-linked glycosylation sites

• Search patterns: ASN-X-SER/THR

```
6-NST-8
90-NFS-92
119-NHT-121
221-NIT-223
255-NIS-257
300-NST-302
488-NFS-490
512-NDS-514
```

1.3 Secondary structure fraction

The fraction of amino acids that tend to be found in the three classical secondary structures. These are beta sheets, alpha helixes, and turns (where the residues change direction).

• Amino acids in helix: V, I, Y, F, W, L.


• Amino acids in turn: N, P, G, S.

• Amino acids in sheet: E, M, A, L.



1.4 Secondary structure prediction

Protein secondary structure prediction is one of the most important and challenging problems in bioinformatics. Here in, the P-SEA algorithm that to predict the secondary structures of proteins sequences based only on knowledge of their primary structure.



1.5 Structural analysis

1.5.1 Detection of disulfide bonds

This function detects disulfide bridges in protein structures. Then the detected disulfide bonds are visualized and added to the bonds attribute of the AtomArray. The employed criteria for disulfide bonds are quite simple in this case: the atoms of two cystein residues must be in a vicinity of \mathring{A} and the dihedral angle of must be .

```
171 CYS SG
                         16.601
                 S
Α
    184 CYS SG
                         18.540 32.510 142.815
                        26.896 13.750 106.306
    422 CYS SG
                 S
Δ
    432 CYS SG
                 S
Α
                        27.418 11.787 106.401
Α
    422 CYS SG
                 S
                        26.896 13.750 106.306
    432 CYS SG
                 S
                        27.418 11.787 106.401
```

```
KeyError
                                          Traceback (most recent call last)
Input In [11], in <cell line: 104>()
     99     print(knottin[sg2_index])
    101 # Create a sequence object for each residue in the structure
    102 # As we want each residue to appear only once in the sequence,
    103 # we choose an atom that appears in each residue once: the CA
--> 104 sequence = seq.ProteinSequence(knottin.res_name[knottin.atom_name == "CA"])
    105 figure = plt.figure(figsize=(10, 1))
    106 ax = figure.gca()
File ~/Downloads/ProDevAnalysis/venv/lib/python3.10/site-packages/biotite/sequence/
 ⇔seqtypes.py:471, in ProteinSequence.__init__(self, sequence)
    468 alph = ProteinSequence.alphabet
    469 # Convert 3-letter codes to single letter codes,
    470 # if list contains 3-letter codes
--> 471 sequence = [dict_3to1[symbol.upper()] if len(symbol) == 3
                    else symbol.upper() for symbol in sequence]
    473 super().__init__(sequence)
File ~/Downloads/ProDevAnalysis/venv/lib/python3.10/site-packages/biotite/sequence/

seqtypes.py:471, in <listcomp>(.0)
    468 alph = ProteinSequence.alphabet
    469 # Convert 3-letter codes to single letter codes,
    470 # if list contains 3-letter codes
--> 471 sequence = [dict_3to1[symbol.upper()] if len(symbol) == 3
                    else symbol.upper() for symbol in sequence]
    473 super().__init__(sequence)
KeyError: 'ALS'
```

The found disulfide bonds are visualized with the help of Matplotlib: The amino acid sequence is written on the X-axis and the disulfide bonds are depicted by yellow semi-ellipses.

1.5.2 Calculation of protein diameter

This calculates the diameter of a protein defined as the maximum pairwise atom distance.

```
# Diameter of H_01C73 is: ------116.214 Angstrong.
```

1.6 Protein Scales


Protein scales are a way of measuring certain attributes of residues over the length of the peptide sequence using a sliding window. Scales are comprised of values for each amino acid based on different physical and chemical properties, such as hydrophobicity, secondary structure tendencies, and surface accessibility. As opposed to some chain-level measures like overall molecule behavior, scales allow a more granular understanding of how smaller sections of the sequence will behave.

- kd → Kyte & Doolittle Index of Hydrophobicity
- Flex → Normalized average flexibility parameters (B-values)
- hw → Hopp & Wood Index of Hydrophilicity
- em → Emini Surface fractional probability (Surface Accessibility)

1.6.1 Hydrophobicity index


hydrophobicity is the physical property of a molecule that is seemingly repelled from a mass of water (known as a hydrophobe).

1.6. Protein Scales 9




1.6.2 Hydrophilicity index

Hydrophilicity is the tendency of a molecule to be solvated by water.




1.6.3 Flexibility index

Proteins are dynamic entities, and they possess an inherent flexibility that allows them to function through molecular interactions within the cell.



1.6.4 Surface accessibility


Data describing the solvent-accessible surface of a molecule is of great utility in the development of that molecule as a therapeutic, particularly in the case of antibodies. In the context of this report, the most obvious application of molecular surface data is in combination with the potential sites of chemical modification, described in the previous section. Proteins are known to undergo many different chemical modifications as a result of interactions with their aqueous environment. The probability and kinetic rate of such a modification is greatly enhanced by the degree of exposure of the potential modification site to the solvent environment. The solvent-accessible surface for each residue depends upon the degree of exposure of the residue on the surface, but also on the size of the residue side chain.



1.6. Protein Scales

1.6.5 Instability index

The instability index provides an estimate of the stability of your protein in a test tube. Statistical analysis of 12 unstable and 32 stable proteins has revealed that there are certain dipeptides, the occurence of which is significantly different in the unstable proteins compared with those in the stable ones.



CHAPTER

TWO

IMMUNOGENICITY ANALYSIS

We uses the method of removing and/or reducing potential T-cell epitopes, as an approach to the management of the immunogenicity of biologics. The protein sequence is scanned in silico, for sequences that have a strong binding signature for a family of 50 MHC Class II receptors , whose alleles cover 96 - 98% of the human population. The presented histograms for each variable region sequence, show the average (for the n positively-testing MHC II alleles) of epitope strength at each position as a percentage for all epitopes above a threshold of 20%. At each position in the sequence, the number of alleles scoring above the threshold is shown above the histogram at that position. The epitopes of most concern for the antibody's immunogenicity are therefore those that have not just the highest average score per allele (as shown by the histogram), but which also score above the threshold across more alleles, since these epitopes are more likely to engender an immune response in a larger fraction of the patient population.

Experience using in silico algorithms of this kind in conjunction with laboratory immunogenicity assays has shown that epitopes below this threshold do not generally contribute significantly to the protein's immunogenicity. The number of alleles, the affected alleles and their individual scores are also listed in the detailed analyses below each histogram figure.

The raw immunogenicity score quoted is the total over all epitopes above the threshold for all affected alleles. The normalized immunogenicity score is this raw score divided by the sequence length, and represents epitope strength per unit sequence to enable comparisons of protein sequences of different lengths.

2.1 MHC class 1


Class I major histocompatibility complex (MHC) molecules bind, and present to T cells, short peptides derived from intracellular processing of proteins. The peptide repertoire of a specific molecule is to a large extent determined by the molecular structure accommodating so-called main anchor positions of the presented peptide.

Their function is to display peptide fragments of proteins from within the cell to cytotoxic T cells; this will trigger an immediate response from the immune system against a particular non-self antigen displayed with the help of an MHC class I protein. Because MHC class I molecules present peptides derived from cytosolic proteins, the pathway of MHC class I presentation is often called cytosolic or endogenous pathway.¹


- MHC class 1 superset
 - HLA-A01:01, HLA-A02:01, HLA-A03:01, HLA-A24:02, HLA-B07:02, HLA-B40:01

¹ Kimball's Biology Pages, Histocompatibility Molecules


2.1.1 Predicts binding of peptides to MHC class1



2.1.2 Top10 strong binding peptide



2.1.3 Frequency of binding peptide




2.2 MHC class 2

MHC Class II molecules are a class of major histocompatibility complex (MHC) molecules normally found only on professional antigen-presenting cells such as dendritic cells, mononuclear phagocytes, some endothelial cells, thymic epithelial cells, and B cells. These cells are important in initiating immune responses.

- MHC class 2 allele superset
 - DRB1_0101,DRB1_0102,DRB1_0103,DRB1_0104,DRB1_0105,DRB1_0106,DRB1_0107,DRB1_0108,DRB1_0109,DRB

2.2.1 Predicts binding of peptides to MHC class2



2.2.2 Top10 binding peptide


	allele	peptide	Core	Rank
0	DRB1_0102	FPTLAGLAGLQVPPR	LAGLAGLQV	0.07
1	DRB1_0104	FPTLAGLAGLQVPPR	LAGLAGLQV	0.08
2	DRB1_0106	FPTLAGLAGLQVPPR	LAGLAGLQV	0.14
3	DRB1_0102	PTLAGLAGLQVPPRC	LAGLAGLQV	0.18
4	DRB1_0106	VPLIFYVPGRTASLP	IFYVPGRTA	0.22
5	DRB1_0102	LFPTLAGLAGLQVPP	LAGLAGLQV	0.23
6	DRB1_0104	PTLAGLAGLQVPPRC	LAGLAGLQV	0.26
7	DRB1_0101	FPTLAGLAGLQVPPR	LAGLAGLQV	0.28

2.2. MHC class 2

(continued from previous page)

```
8 DRB1_0107 FPTLAGLAGLQVPPR LAGLAGLQV 0.28
9 DRB1_0108 FPTLAGLAGLQVPPR LAGLAGLQV 0.28
```

2.2.3 Frequency of binding peptide



2.3 Appendix

nothing yet.